Work Here?
Overview
Sobi specializes in developing and delivering therapies for rare diseases. It focuses on hematology, immunology, and specialty care, bringing medicines to patients who have limited treatment options. Their products are designed to treat rare conditions and are typically administered by prescription under medical supervision; the company collaborates with partners to advance research, develop, and commercialize these therapies. Sobi differentiates itself through its strong biotechnological foundation from its Biovitrum heritage and a track record of strategic collaborations with major pharmaceutical players like Sanofi and Apellis, which expand its research capabilities and reach. The company’s goal is to improve the lives of patients with rare diseases worldwide by creating and delivering effective treatments that address unmet medical needs.
About Sobi
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Solna kommun, Sweden
Founded
1988
Get referred to Sobi
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 29% CER to SEK 7.842 billion, boosting hiring confidence.
- Altuvoct, Doptelet, and Gamifant delivered 149%, 36%, and 29% Q2 growth.
- Tryngolza sHTG filing and positive EAS data expand the 2027 European launch opportunity.
What critics are saying
- FDA issued NASP a June 2026 CMC CRL; resubmission slips launch into 2027.
- Aspaveli UK uptake depends on a pending NICE decision, delaying reimbursement.
- Guido Oelkers exits by January 2027, risking execution drift during multiple launches.
What makes Sobi unique
- Sobi dominates rare-disease commercialization across hemophilia, immunology, and nephrology globally.
- Aspaveli launched first-in-class C3G and IC-MPGN therapy in Europe in January 2026.
- Arthrosi and NASP deepen gout leadership, pairing late-stage assets with global reach.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$363M
Above
Industry Average
Funded Over
1 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Tuition Reimbursement
Wellness Program
Stock Price
Growth & Insights and Company News
6 month growth
↑ 11%1 year growth
↑ 11%2 year growth
↑ 11%Swedish biopharmaceutical company Sobi (Swedish Orphan Biovitrum) is acquiring full ownership of Pint Pharma, a firm specialising in bringing complex treatments, including cancer therapies, to Latin American markets. The transaction builds on Sobi's initial investment last year, when it paid $105 million for most of Pint's economic rights. The deal, submitted to Brazil's competition authority Cade, involves purchasing all remaining shares of Pharma Investments, Pint's parent company. The transaction value remains undisclosed. The acquisition gives Sobi control of a platform operating across seven Latin American markets, including Brazil, Mexico, Argentina, and Colombia. Pint handles regulatory approval, market access, and distribution of specialised medicines for rare diseases, haematology, and oncology. Sobi reported revenue of 28.2 billion Swedish kronor (approximately $2.9 billion) in 2025. The companies have maintained a commercial partnership since 2021.
Swedish biopharma firm Sobi announced that chief executive Guido Oelkers will step down to take up another position outside the company. Oelkers will continue in his role until the end of January 2027 at the latest. "Leading Sobi has been a privilege, and I am proud of what we have accomplished together as a team," Oelkers said. He highlighted advancing the pipeline, expanding global footprint, and growing Sobi into a leader in rare diseases. The company will immediately begin searching for a new chief executive. Sobi's operations, strategy, and financial targets remain unchanged, the firm said.
Swedish Orphan Biovitrum (Sobi) is repurchasing shares to support its employee incentive programme. The Board of Directors exercised authorisation granted at the May 2026 Annual General Meeting to repurchase class C shares at approximately SEK 0.55 per share, representing 100% of their quotient value. The repurchase involves 223,677 shares and will occur between 16 July and 6 November 2026. Svenska Handelsbanken will handle the transaction. After converting the repurchased class C shares to common shares, Sobi will hold 10,290,974 own shares. The move secures commitments under the All Employee Programme, a long-term incentive scheme for permanent staff. Sobi, a biopharma company focused on rare diseases, employs approximately 2,000 people globally and reported revenue of SEK 28 billion in 2025.
Enable Injections has received CE Certification for its enFuse On-Body Delivery System for use with Aspaveli (pegcetacoplan), which will be distributed by Swedish Orphan Biovitrum across the European Union as ASPAVELI enFuse. The certification allows caregivers and patients aged 12 and older to use the wearable device for subcutaneous drug administration. The enFuse system delivers medication through a discreet, hands-free device using a small, hidden needle, designed to improve patient self-administration. Aspaveli is approved for treating paroxysmal nocturnal haemoglobinuria, C3G and primary IC-MPGN in patients 12 years and older. This follows recent regulatory clearances in Saudi Arabia, Brazil, South Korea and Canada, part of Enable's strategic partnership with Sobi announced in September 2024.
Swedish Orphan Biovitrum (Sobi) held its annual general meeting on 6 May 2026, approving several key resolutions. Shareholders adopted the company's financial statements for 2025 and discharged the board and CEO from liability. David Meek was re-elected as board chair, with Christophe Bourdon, Iris Loew-Friedrich, Staffan Schüberg and Filippa Stenberg re-elected as directors. Mikael Dolsten and Åsa Riisberg joined as new board members. Ernst & Young was re-appointed as auditor. The AGM approved long-term incentive programmes, including an employee programme with up to 223,677 series C shares and a management programme via equity swap. The board received authorisation to issue up to 39,710,000 new shares through various instruments. Sobi reported SEK 28 billion in revenue for 2025.
Sobi is Hiring for 77 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Sobi
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Solna kommun, Sweden
Founded
1988
Sobi is Hiring for 77 Jobs on Simplify!
Find jobs on Simplify and start your career today